Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study

Trial Profile

Lengthening Adalimumab Dosing Interval in IBD patients in long term remission, the LADI study

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms LADI
  • Most Recent Events

    • 02 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top